All News

Jan
23
2023

Analyst Group comments on AcouSort’s expanded cell therapy collaboration

Read the full comment (in Swedish) here: https://analystgroup.se/kommentarer/analyst-group-kommenterar-acousorts-utokade-cellterapisamarbete/.

Read More
Jan
23
2023

CEO Torsten Freltoft summarizes 2022

For AcouSort, 2022 was in many ways a good year. As the pandemic restrictions were lifted, we were able to intensify our important marketing work while strengthening our commercial organization

Read More
Jan
20
2023

Extended collaboration targeting cell therapies generates revenues of EUR 130,000 in 2023

In November 2022, AcouSort reported that the company had entered a collaboration with a global life science company active within the cell therapy field. The first part of the project

Read More
Jan
19
2023

AcouSort and BlueCell in commercial planning as the stem cell therapy project Blue4Therapy approaches completion

The Blue4Therapy project was initiated in May 2020 with the ambition to develop clinical applications in cell therapy and stem cell treatments – two areas with great commercial potential. Behind

Read More
Dec
5
2022

Two of AcouSort’s board members and CEO acquire shares

AcouSort AB (publ) (“AcouSort” or the “Company”) today announces that founders and board members Thomas Laurell and Stefan Scheding as well as CEO Torsten Freltoft have acquired shares in the

Read More
Dec
1
2022

The BioWings project creates new opportunities for large-scale production and exosome-based diagnostics

AcouSort and its collaborators are now finishing the 4-year BioWings project which has developed new thin-film materials generating the ultrasound necessary to move cells in AcouSort’s chips. The new materials

Read More
Nov
24
2022

AcouSort presents at Stora Aktiedagen in Stockholm, November 30, addressing current developments in the vibrant cell therapy space

On November 30, 2022, CEO Torsten Freltoft will present at Stora Aktiedagen in Stockholm. In his presentation, Torsten will talk about the company’s continuous advancements in the cell therapy space,

Read More
Nov
23
2022

AcouSort Interim Report Q3, 2022

Today, November 23, 2022, AcouSort is releasing its Interim Report for Q3, 2022. The report is available both in Swedish and English and can be found here AcouSort AB Q3

Read More
Nov
14
2022

AcouSort expands its cell therapy efforts and enters collaboration with global life science company

Cell therapy is an area where AcouSort sees great potential for the company’s technology. Initially, AcouSort aims at enabling the automation of cell therapy preparation with its AcouWash technology. In

Read More
Nov
11
2022

AcouSort to supply Lund University with unique pre-focusing technology to enable high precision cell separation

AcouSort has received an order from Lund University to develop and deliver a modified AcouWash2 system with a unique pre-focusing feature to enable high precision cell separation of circulating tumor

Read More